When does Alembic’s Vitrakvi (larotrectinib) lose exclusivity?
No dates for Alembic’s loss of exclusivity for Vitrakvi are provided in the supplied information. Exclusivity timing depends on the specific country and on the type of exclusivity involved (patent expiry, regulatory/data exclusivity, or any other marketing exclusivity granted by that regulator).
If you share the country (for example, India, the US, or EU countries) and whether you mean patent expiry or regulatory exclusivity, I can narrow down what “loss of exclusivity” would mean there.
What counts as “exclusivity” for Vitrakvi—patent expiry or regulatory exclusivity?
For branded oncology medicines like Vitrakvi (larotrectinib), “loss of exclusivity” typically refers to one or more of the following mechanisms:
- Patent expiry (covering the drug substance/composition, methods of use, or related claims).
- Regulatory data exclusivity and marketing exclusivity (time limits that can block approval of certain competitors even if patents expire, or vice versa).
- Any jurisdiction-specific exclusivity periods tied to new indications, formulations, or pediatric extensions.
Those categories often have different end dates, so the exact “loss of exclusivity” date varies by what you mean.
How does this affect when generics or biosimilars can enter?
If a competitor’s product approval is blocked by:
- Active patents, then generics/competitors may not be able to launch even after regulatory exclusivity ends.
- Regulatory/data exclusivity, then approval can be delayed even if patents are no longer enforceable.
The earliest launch date is usually the later constraint among the applicable patents and regulatory exclusivity in the target jurisdiction.
Why might Alembic’s “Vitrakvi” exclusivity timeline differ by country?
Companies often file different patent families in different jurisdictions, and regulatory exclusivity rules differ across countries. That means “exclusivity loss” could occur earlier in one country and later in another.
What to look up to get the exact Alembic Vitrakvi loss-of-exclusivity date
To identify the actual date, you typically need:
- The target country.
- The exact product/strength and whether you’re tracking the brand or an approved generic/marketing authorization.
- The relevant patent list for larotrectinib in that jurisdiction.
- The regulator’s listed periods for data/marketing exclusivity for that authorization.
Send the country and whether you’re asking about patents or regulatory exclusivity, and I’ll help you translate that into an actionable timeline.
Sources
No sources were provided with the question, so no citations can be included.